Clinical trial · Interventional
Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer
A Phase II Study on the Safety and Efficacy of Radiation Therapy and Concurrent Erlotinib in Locally Advanced Non-small-cell Lung Cancer
NCT00973310CI-TRIAL-00020285unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety and efficacy of the concurrent use of erlotinib and radiation therapy in the treatment of locally advanced non-small lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiation Therapy and EGFR-TKI target therapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Combined Treatment arm
- description
- All the patients received oral erlotinib and concurrent radiation therapy
- interventionNames
- Other: Radiation Therapy and EGFR-TKI target therapy
Primary outcomes (1)
- measure
- Evidence of clinically definite disease progression
- timeFrame
- 3 year
Secondary outcomes (1)
- measure
- All cause mortality and any grade III and above toxicities
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18-70 years， * Patients with stage IIIA-IIIB NSCLC * adequate hematologic (WBC and platelet counts within normal limits), hepatic (total bilirubin level \<= two times the upper limit of normal), and renal (creatinine clearance \>= 50mL/min) functions * No history of chemotherapy or less than 4 cycles neoadjuvant chemotherapy * Can not tolerate or refuse concurrent chemoradiotherapy * No history of thoracic RT * Written informed consent obtained Exclusion Criteria: * With other malignancy * With severe cardiopulmonary disease * Compromised liver or renal function that could not tolerate the combined therapy * Received thoracic RT before * Pregnant or breast-feeding women * Present with active infection * Uncontrolled diabetes * Concurrent use of other anti-cancer agents
References
Publications (1)
- DERIVEDZhuang H, Hou H, Yuan Z, Wang J, Pang Q, Zhao L, Wang P. Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy. Onco Targets Ther. 2014 May 24;7:807-13. doi: 10.2147/OTT.S62707. eCollection 2014. PMID 24920921